Exhibiting a Combination of SOS1:KRAS Inhibitor with A MEK Inhibitor Reconfigures the Immune Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinomas & Sensitizes to Immunotherapy
Time: 11:45 am
day: Day Two Track B AM
Details:
- Showcasing the efficacy of SOS1i and MEKi as monotherapy and combination in controlling KPCY tumor growth in vitro and in vivo
- Presenting how the combination of SOS1 and MEK inhibition rewires the immune tumor microenvironment
- Displaying how CD8+ T cells increase is restricted to the individual tumor site and resulted from both recruitment and intra-tumoral division, suggesting tumor-specific T cell clonal expansion
- Understanding how a combination of SOS1 and MEK with immunotherapy prolongs tumor regressions and induces memory
